Department of Biostatistics, China Pharmaceutical University, Nanjing, China.
J Cancer Res Clin Oncol. 2023 Sep;149(11):9151-9165. doi: 10.1007/s00432-023-04831-x. Epub 2023 May 13.
HGSOC is a kind of gynecological cancer with high mortality and strong heterogeneity. The study used multi-omics and multiple algorithms to identify novel molecular subtypes, which can help patients obtain more personalized treatments.
Firstly, the consensus clustering result was obtained using a consensus ensemble of ten classical clustering algorithms, based on mRNA, lncRNA, DNA methylation, and mutation data. The difference in signaling pathways was evaluated using the single-sample gene set enrichment analysis (ssGSEA). Meanwhile, the relationship between genetic alteration, response to immunotherapy, drug sensitivity, prognosis, and subtypes was further analyzed. Finally, the reliability of the new subtype was verified in three external datasets.
Three molecular subtypes were identified. Immune desert subtype (CS1) had little enrichment in the immune microenvironment and metabolic pathways. Immune/non-stromal subtype (CS2) was enriched in the immune microenvironment and metabolism of polyamines. Immune/stromal subtype (CS3) not only enriched anti-tumor immune microenvironment characteristics but also enriched pro-tumor stroma characteristics, glycosaminoglycan metabolism, and sphingolipid metabolism. The CS2 had the best overall survival and the highest response rate to immunotherapy. The CS3 had the worst prognosis and the lowest response rate to immunotherapy but was more sensitive to PARP and VEGFR molecular-targeted therapy. The similar differences among three subtypes were successfully validated in three external cohorts.
We used ten clustering algorithms to comprehensively analyze four types of omics data, identified three biologically significant subtypes of HGSOC patients, and provided personalized treatment recommendations for each subtype. Our findings provided novel views into the HGSOC subtypes and could provide potential clinical treatment strategies.
HGSOC 是一种死亡率高、异质性强的妇科癌症。本研究采用多组学和多种算法来识别新的分子亚型,这有助于患者获得更个性化的治疗。
首先,基于 mRNA、lncRNA、DNA 甲基化和突变数据,使用十种经典聚类算法的共识集成来获得共识聚类结果。使用单样本基因集富集分析(ssGSEA)评估信号通路的差异。同时,进一步分析遗传改变、免疫治疗反应、药物敏感性、预后与亚型的关系。最后,在三个外部数据集验证新亚型的可靠性。
鉴定出三个分子亚型。免疫荒漠亚型(CS1)的免疫微环境和代谢途径无明显富集。免疫/非基质亚型(CS2)富含免疫微环境和多胺代谢。免疫/基质亚型(CS3)不仅富集抗肿瘤免疫微环境特征,还富集促肿瘤基质特征、糖胺聚糖代谢和鞘脂代谢。CS2 的总生存期最好,免疫治疗反应率最高。CS3 的预后最差,免疫治疗反应率最低,但对 PARP 和 VEGFR 分子靶向治疗更敏感。三个外部队列中成功验证了三个亚型之间的相似差异。
我们使用十种聚类算法全面分析了四种组学数据,鉴定了 HGSOC 患者的三个具有生物学意义的亚型,并为每个亚型提供了个性化的治疗建议。我们的发现为 HGSOC 亚型提供了新的视角,并为潜在的临床治疗策略提供了依据。